BioLife Solutions Announces Closing of Stirling Ultracold Acquisition and Expanded Partnership with Leading Global Biopharma CDMO
BioLife Solutions (BLFS) has completed the acquisition of Stirling Ultracold, issuing 6,646,870 shares for 100% of Stirling's outstanding shares. Expected revenue contribution from Stirling for 2021 is $35 million to $37 million, contributing to BioLife's total projected revenue of $101 million to $110 million. Stirling will supply 100 ultra-low temperature freezers to a leading CDMO, expanding their partnership. CEO Mike Rice anticipates cross-selling opportunities with BioLife's bioproduction tools, enhancing market reach in cell and gene therapies.
- Acquisition of Stirling Ultracold expected to add $35M-$37M to 2021 revenue.
- Total projected revenue for BioLife in 2021 is $101M-$110M.
- Expanded partnership with a leading global CDMO enhances market presence.
- Cross-selling opportunities anticipated with BioLife's existing product portfolio.
- None.
BOTHELL, Wash., May 3, 2021 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of a portfolio of class-defining bioproduction products and services for cell and gene therapies and the broader biopharma market, today announced that it has closed the previously announced acquisition of Stirling Ultracold ("Stirling"), a privately held manufacturer of ultra-low temperature ("ULT") mechanical freezers. BioLife issued 6,646,870 shares of common stock in exchange for
BioLife management has provided guidance for Stirling's 2021 post-closing revenue contribution to be
BioLife also announced that Stirling has expanded its existing partnership with a leading global contract development and manufacturing organization (CDMO) and has been selected by this customer as their preferred provider of ULT storage across their multiple business units. Stirling will supply approximately 100 energy-efficient ULT mechanical freezers to support this customer's cold chain capabilities for biologics and emerging modalities. This augments the existing installed base of 200 Stirling freezers across this CDMO's worldwide facilities footprint.
Mike Rice, BioLife CEO, commented, "We welcome Dusty Tenney in his new role as BioLife's president and chief operating officer. Dusty and the entire Stirling team continue to deliver innovative solutions and stellar support to cell and gene therapy developers and contract manufacturing companies. We are realizing the cross-selling leverage we anticipated via our M&A strategy, as this customer uses our entire bioproduction tools and services portfolio. In addition to Stirling freezers, our proprietary CryoStor® biopreservation media, automated, water-free ThawSTAR® thaw systems, evo® cold chain management platform, CBS cryogenic freezers and SciSafe storage services are all used to optimized the manufacture, storage, transport and thawing of life-saving cell and gene therapies. We see a tremendous opportunity to cross-sell our entire bioproduction tools and services portfolio to companies in the cell and gene therapy and broader biopharma markets."
About Stirling Ultracold
Stirling Ultracold manufactures and sells environmentally sustainable ultra-low temperature (ULT) freezers for the global market. Powered by the free-piston Stirling engine, and the first in the U.S. to use
About BioLife Solutions
BioLife Solutions is a leading supplier of class-defining cell and gene therapy bioproduction tools and services. Our tools portfolio includes our proprietary CryoStor® freeze media and HypoThermosol® shipping and storage media, ThawSTAR® family of automated, water-free thawing products, evo® cold chain management system, Custom Biogenic Systems high capacity storage freezers, Stirling Ultracold mechanical freezers and SciSafe biologic storage services. For more information, please visit www.biolifesolutions.com, and follow BioLife on Twitter.
Cautions Regarding Forward Looking Statements
Except for historical information contained herein, this presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, statements concerning the expected financial performance of the company following the completion of its acquisition of Global Cooling and its 2019 and 2020 acquisitions and giving effect to the COVID-19 pandemic, the company's ability to implement its business strategy and anticipated business and operations, in particular following its acquisition of Global Cooling, the expected synergies between the company and Global Cooling, the company's ability to realize all or any of the anticipated benefits associated with the acquisition of Global Cooling, the company's ability to implement its business strategy and anticipated business and operations, including its ability to cross-sell its product offerings, the potential utility of and market for the company's products and services, guidance for financial results for 2021, including regarding Global Cooling's contribution of revenue, and potential revenue growth and market expansion, including with consideration to its 2019, 2020 and 2021 acquisitions and giving effect to the COVID-19 pandemic, the company's anticipated future growth strategy, including the acquisition of synergistic cell and gene therapy manufacturing tools and services or technologies, the potential utility of and market for our products and services, potential revenue growth and market expansion, regulatory approvals and/or commercial manufacturing of our customers' products, and potential customer revenue. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. These statements are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements, including among other things, uncertainty regarding unexpected costs, charges or expenses resulting from the acquisition of Global Cooling (or from the company's 2019 and 2020 acquisitions), market adoption of the company's products (including the company's recently acquired products); the ability of company's 2019, 2020 and 2021 acquisitions to be accretive on the company's financial results; the ability of the company to continue to implement its business strategy; uncertainty regarding third-party market projections; market volatility; competition; litigation; the impact of the COVID-19 pandemic; and those other factors described in our risk factors set forth in our filings with the Securities and Exchange Commission from time to time, including our Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. We undertake no obligation to update the forward-looking statements contained herein or to reflect events or circumstances occurring after the date hereof, other than as may be required by applicable law.
Media & Investor Relations
Roderick de Greef
Chief Financial Officer & Chief Operating Officer
(425) 686-6002
rdegreef@biolifesolutions.com
View original content to download multimedia:http://www.prnewswire.com/news-releases/biolife-solutions-announces-closing-of-stirling-ultracold-acquisition-and-expanded-partnership-with-leading-global-biopharma-cdmo-301282466.html
SOURCE BioLife Solutions, Inc.
FAQ
What is the current stock symbol of BioLife Solutions after the acquisition?
When was the acquisition of Stirling Ultracold completed by BioLife Solutions?
How much revenue is Stirling Ultracold expected to contribute in 2021?
What is the total projected revenue for BioLife Solutions in 2021?
What role will Stirling Ultracold play in BioLife's operations?
